The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer

The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2017-07, Vol.28 (7), p.1667-1668
Hauptverfasser: Seo, S., Woo, C.G., Lee, D.H., Choi, J.
Format: Artikel
Sprache:eng
Schlagworte:
Carcinoma, Non-Small-Cell Lung
Crizotinib
Humans
Lung Neoplasms
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Receptor Protein-Tyrosine Kinases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1668
container_issue 7
container_start_page 1667
container_title Annals of oncology
container_volume 28
creator Seo, S.
Woo, C.G.
Lee, D.H.
Choi, J.
description
doi_str_mv 10.1093/annonc/mdx185
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1888681079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419322768</els_id><sourcerecordid>1888681079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-a92c6de25a2b159d1b3cb5324a1c9beba8500de6246d88bad6cb49f32df457d73</originalsourceid><addsrcrecordid>eNp1kbtuFTEURS0EIpckJS1ySWPixzzsMooSQNwoTahHZ2xPYuSxL7ZnAvwJf4uvJtBR-aGlpXP2Rugtox8YVeICQohBX8zmB5PtC7RjbaeIpA17iXZUcUH6VjQn6E3O3yilneLqNTrhsqE9Fd0O_b5_tFh7F5wGj918AF1wnDAEfH27b8jl_gteITkI9TvgvKTVrZWcovfxyYUHrJP7FUsVjLgkC2W2FXUBH6C4es34yZVHDGaFoK3BVUgqlhKEh_qsw5M8g_dEW--xX47GI5nO0KsJfLbnz-cp-npzfX_1iezvPn6-utwTLSQtBBTXnbG8BT6yVhk2Cj22gjfAtBrtCLKl1NiON52RcgTT6bFRk-Bmatre9OIUvd-8hxS_LzaXYXb5OAwEG5c8MCllJxntVUXJhuoUc052Gg7JzZB-DowOxzaGrY1ha6Py757Vyzhb84_-G38F-g2wdcHV2TRkXUOrOblkdRlMdP9R_wEBt56d</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1888681079</pqid></control><display><type>article</type><title>The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Seo, S. ; Woo, C.G. ; Lee, D.H. ; Choi, J.</creator><creatorcontrib>Seo, S. ; Woo, C.G. ; Lee, D.H. ; Choi, J.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx185</identifier><identifier>PMID: 28407036</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Carcinoma, Non-Small-Cell Lung ; Crizotinib ; Humans ; Lung Neoplasms ; Oncogene Proteins, Fusion ; Protein Kinase Inhibitors ; Pyrazoles ; Pyridines ; Receptor Protein-Tyrosine Kinases</subject><ispartof>Annals of oncology, 2017-07, Vol.28 (7), p.1667-1668</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-a92c6de25a2b159d1b3cb5324a1c9beba8500de6246d88bad6cb49f32df457d73</citedby><cites>FETCH-LOGICAL-c380t-a92c6de25a2b159d1b3cb5324a1c9beba8500de6246d88bad6cb49f32df457d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28407036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seo, S.</creatorcontrib><creatorcontrib>Woo, C.G.</creatorcontrib><creatorcontrib>Lee, D.H.</creatorcontrib><creatorcontrib>Choi, J.</creatorcontrib><title>The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><subject>Carcinoma, Non-Small-Cell Lung</subject><subject>Crizotinib</subject><subject>Humans</subject><subject>Lung Neoplasms</subject><subject>Oncogene Proteins, Fusion</subject><subject>Protein Kinase Inhibitors</subject><subject>Pyrazoles</subject><subject>Pyridines</subject><subject>Receptor Protein-Tyrosine Kinases</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kbtuFTEURS0EIpckJS1ySWPixzzsMooSQNwoTahHZ2xPYuSxL7ZnAvwJf4uvJtBR-aGlpXP2Rugtox8YVeICQohBX8zmB5PtC7RjbaeIpA17iXZUcUH6VjQn6E3O3yilneLqNTrhsqE9Fd0O_b5_tFh7F5wGj918AF1wnDAEfH27b8jl_gteITkI9TvgvKTVrZWcovfxyYUHrJP7FUsVjLgkC2W2FXUBH6C4es34yZVHDGaFoK3BVUgqlhKEh_qsw5M8g_dEW--xX47GI5nO0KsJfLbnz-cp-npzfX_1iezvPn6-utwTLSQtBBTXnbG8BT6yVhk2Cj22gjfAtBrtCLKl1NiON52RcgTT6bFRk-Bmatre9OIUvd-8hxS_LzaXYXb5OAwEG5c8MCllJxntVUXJhuoUc052Gg7JzZB-DowOxzaGrY1ha6Py757Vyzhb84_-G38F-g2wdcHV2TRkXUOrOblkdRlMdP9R_wEBt56d</recordid><startdate>201707</startdate><enddate>201707</enddate><creator>Seo, S.</creator><creator>Woo, C.G.</creator><creator>Lee, D.H.</creator><creator>Choi, J.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201707</creationdate><title>The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer</title><author>Seo, S. ; Woo, C.G. ; Lee, D.H. ; Choi, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-a92c6de25a2b159d1b3cb5324a1c9beba8500de6246d88bad6cb49f32df457d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Carcinoma, Non-Small-Cell Lung</topic><topic>Crizotinib</topic><topic>Humans</topic><topic>Lung Neoplasms</topic><topic>Oncogene Proteins, Fusion</topic><topic>Protein Kinase Inhibitors</topic><topic>Pyrazoles</topic><topic>Pyridines</topic><topic>Receptor Protein-Tyrosine Kinases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seo, S.</creatorcontrib><creatorcontrib>Woo, C.G.</creatorcontrib><creatorcontrib>Lee, D.H.</creatorcontrib><creatorcontrib>Choi, J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seo, S.</au><au>Woo, C.G.</au><au>Lee, D.H.</au><au>Choi, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2017-07</date><risdate>2017</risdate><volume>28</volume><issue>7</issue><spage>1667</spage><epage>1668</epage><pages>1667-1668</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28407036</pmid><doi>10.1093/annonc/mdx185</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2017-07, Vol.28 (7), p.1667-1668
issn 0923-7534
1569-8041
language eng
recordid cdi_proquest_miscellaneous_1888681079
source MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Carcinoma, Non-Small-Cell Lung
Crizotinib
Humans
Lung Neoplasms
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Receptor Protein-Tyrosine Kinases
title The clinical impact of an EML4-ALK variant on survival following crizotinib treatment in patients with advanced ALK-rearranged non-small-cell lung cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T19%3A45%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20impact%20of%20an%20EML4-ALK%20variant%20on%20survival%20following%20crizotinib%20treatment%20in%20patients%20with%20advanced%20ALK-rearranged%20non-small-cell%20lung%20cancer&rft.jtitle=Annals%20of%20oncology&rft.au=Seo,%20S.&rft.date=2017-07&rft.volume=28&rft.issue=7&rft.spage=1667&rft.epage=1668&rft.pages=1667-1668&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx185&rft_dat=%3Cproquest_cross%3E1888681079%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1888681079&rft_id=info:pmid/28407036&rft_els_id=S0923753419322768&rfr_iscdi=true